Dupixent approved in the US as the first-ever biologic medicine …
WEBSep 27, 2024 · Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype; Following recent approvals in the EU and China, the US approval is based on two landmark phase 3 studies that showed Dupixent achieved significant reduction in exacerbations, and also showed improvements in lung function and health-related quality of life ...
FDA approves Dupixent for chronic obstructive pulmonary disease
WEB2 days ago · The U.S. Food and Drug Administration has approved Regeneron's Dupixent (dupilumab) as an add-on maintenance treatment for adults with inadequately controlled chronic obstructive pulmonary disease ...
Sanofi-Regeneron's Dupixent wins FDA's nod for 'smoker's lung'
WEBSep 27, 2024 · Sanofi last year recorded a combined 10.72 billion euros ($11.94 billion) in sales for Dupixent, which is already used to treat immune system-related conditions such as asthma and eczema in the U ...
Dupixent Gets FDA Approval for COPD - WebMD
WEB2 days ago · Oct. 2, 2024 — The FDA has approved Regeneron and Sanofi’s drug Dupixent for patients with COPD (chronic obstructive pulmonary disease). Marking the sixth indication for the drug, the approval ...
Dupixent® (dupilumab) Approved in the U.S. as the First-ever …
WEBSep 27, 2024 · Dupixent is indicated for the approximately 300,000 adults in the U.S. with inadequately controlled chronic obstructive pulmonary disease (COPD) and an eosinophilic phenotype Following recent ...
Blockbuster Dupixent wins FDA approval for COPD - STAT
WEBDupixent is already a blockbuster therapy for a range of immune-mediated diseases, but the Food and Drug Administration’s approval of the drug for chronic obstructive …
Press Release: Dupixent approved in the US as the first-ever …
WEBSep 27, 2024 · Dupixent approved in the US as the first-ever biologic medicine for patients with COPD Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an ...
Press Release: Dupixent is the first and only biologic to ... - Sanofi
WEBSep 11, 2024 · Dupixent is the first medication to show significant and robust impacts in this patient population. These latest pivotal results reaffirm the underlying role type-2 inflammation plays in driving multiple skin diseases.
Dupixent® (dupilumab) Is the First and Only Biologic to Achieve ...
WEBTrial met the primary and all key secondary endpoints in adults with moderate-to-severe disease; five times more patients achieved sustained disease remission with Dupixent …
FDA, after delay, clears Regeneron and Sanofi drug for COPD
WEBThe Food and Drug Administration on Friday approved Regeneron Pharmaceuticals and Sanofi’s inflammatory disease drug Dupixent for a common lung condition. The decision …
- Some results have been removed